Apostle Inc Appoints David B. Goldstein, PhD at Columbia University to Scientific Advisory Board
Apostle Inc is pleased to announce the appointment of David B. Goldstein, PhD as a new member to its Scientific Advisory Board. Dr. Goldstein is John E. Borne Professor of Medical and Surgical Research at Columbia University.
Menlo Park, CA, February 11, 2018 --(PR.com)-- Apostle Inc is pleased to announce the appointment of David B. Goldstein, PhD as a new member to its Scientific Advisory Board. Dr. Goldstein is John E. Borne Professor of Medical and Surgical Research at Columbia University. He is Director of Institute for Genomic Medicine at Columbia University Medical Center. Dr. Goldstein received his PhD degree in Theoretical Population Genetics from Stanford in 1994, and BS in Biology from University of California, Los Angeles.
“I’m pleased to welcome Dr. Goldstein,” said David Ge, CEO and Chairman of Apostle. “David is a renowned leader in genetics and an achieved researcher with a wealth of experience and expertise in human genetic diversity, the genetics of disease, and pharmacogenetics. His advice will add tremendous value to our company as we further our mission of bringing innovative technologies to help our community with the early detection of cancer and other potential clinical applications.”
Dr. Goldstein is Elected Member of AAAS. He was the recipient of Royal Society Wolfson Research Merit Award. His research at Columbia focuses on many aspects of human genetic variation including human genetic diversity, the genetics of disease, and pharmacogenetics.
About Apostle Inc
Apostle Inc is a biotechnology company in Menlo Park, CA. It’s in the business of the research, development, licensing, and sales of novel technologies, and the related intellectual properties, products, and services for diagnosis and treatment of human diseases, to fundamentally improve the accuracy and efficiency of liquid biopsy - the testing of circulating free DNA (cfDNA) - in early cancer detection or other clinical applications such as noninvasive prenatal testing (NIPT), tests for infectious diseases, therapeutics including CAR-T.
More information can be found at www.apostlebio.com.
Contact: info@apostlebio.com
“I’m pleased to welcome Dr. Goldstein,” said David Ge, CEO and Chairman of Apostle. “David is a renowned leader in genetics and an achieved researcher with a wealth of experience and expertise in human genetic diversity, the genetics of disease, and pharmacogenetics. His advice will add tremendous value to our company as we further our mission of bringing innovative technologies to help our community with the early detection of cancer and other potential clinical applications.”
Dr. Goldstein is Elected Member of AAAS. He was the recipient of Royal Society Wolfson Research Merit Award. His research at Columbia focuses on many aspects of human genetic variation including human genetic diversity, the genetics of disease, and pharmacogenetics.
About Apostle Inc
Apostle Inc is a biotechnology company in Menlo Park, CA. It’s in the business of the research, development, licensing, and sales of novel technologies, and the related intellectual properties, products, and services for diagnosis and treatment of human diseases, to fundamentally improve the accuracy and efficiency of liquid biopsy - the testing of circulating free DNA (cfDNA) - in early cancer detection or other clinical applications such as noninvasive prenatal testing (NIPT), tests for infectious diseases, therapeutics including CAR-T.
More information can be found at www.apostlebio.com.
Contact: info@apostlebio.com
Contact
Apostle Inc
David Ge
650-483-5437
apostlebio.com
David Ge
650-483-5437
apostlebio.com
Contact
Categories